BCLI BRAINSTORM CELL THERAPEUTICS INC Business Restructuring 8-K Filing 2023 - Costs Associated with Exit or Disposal Activities Brainstorm Cell Therapeutics Inc. announced a reduction in force of approximately 30% to decrease costs and realign for accelerated development of NurOwn for ALS treatment, with estimated costs of $450,000-$900,000. EVP and Chief Medical Officer, Dr. Kirk Taylor, stepped down.Get access to all SEC 8-K filings of the BRAINSTORM CELL THERAPEUTICS INC